Chimerix Inc CMRX:NASDAQ

Last Price$5.51NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22

Today's Change-0.07(1.25%)
Bid (Size)$5.40 (2)
Ask (Size)$5.51 (1)
Day Low / High$5.42 - 5.72
Volume838.5 K
 

View Biotechnology IndustryPeer Comparison as of 01/21/2022

 

Chimerix Inc ( NASDAQ )

Price: $5.51
Change: -0.07 (1.25%)
Volume: 838.5 K
4:00PM ET 1/21/2022
 
 

Deciphera Pharmaceuticals Inc ( NASDAQ )

Price: $8.04
Change: -0.11 (1.35%)
Volume: 1.3 M
4:00PM ET 1/21/2022
 
 

Lexicon Pharmaceuticals Inc ( NASDAQ )

Price: $3.15
Change: -0.10 (3.08%)
Volume: 530.5 K
4:00PM ET 1/21/2022
 
 

BioXcel Therapeutics Inc ( NASDAQ )

Price: $16.68
Change: -0.75 (4.30%)
Volume: 462.7 K
4:00PM ET 1/21/2022
 
 

bluebird bio Inc ( NASDAQ )

Price: $7.24
Change: +0.31 (4.47%)
Volume: 11.8 M
4:00PM ET 1/21/2022
 

Read more news Recent News

--HC Wainwright Adjusts Chimerix's Price Target to $24 From $21, Keeps Buy Rating
7:03AM ET 12/22/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Biomedical Advanced Research, Development Authority Intends to Negotiate With Chimerix Over Smallpox Therapy Contract
2:16PM ET 11/30/2021 MT Newswires

Chimerix (CMRX) said that the Biomedical Advanced Research and Development Authority intends to negotiate a contract with the company for the development...

--Wedbush Trims Price Target on Chimerix to $14 From $15, Keeps Outperform Rating
6:44AM ET 11/23/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Wedbush Trims Price Target for Chimerix to $14 From $15, Maintains Outperform Rating
2:14PM ET 11/22/2021 MT Newswires

Price: 6.20, Change: +0.22, Percent Change: +3.68 ...

Company Profile

Business DescriptionChimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC. View company web site for more details
Address2505 Meridian Parkway
Durham, North Carolina 27713
Phone+1.919.806.1074
Number of Employees59
Recent SEC Filing01/20/20224
President, Chief Executive Officer & DirectorMichael A. Sherman
Chief Financial & Business OfficerMichael T. Andriole
Chief Scientific OfficerRandall Lanier
Chief Technology & Manufacturing OfficerRoy W. Ware

Company Highlights

Price Open$5.42
Previous Close$5.58
52 Week Range$4.75 - 11.57
Market Capitalization$478.6 M
Shares Outstanding86.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.10
Beta vs. S&P 500N/A
Revenue$7.2 M
Net Profit Margin-4,762.95%
Return on Equity-135.03%

Analyst Ratings as of 04/28/2021

Buy
6
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset